A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02221869 |
|
Recruitment Status :
Completed
First Posted : August 21, 2014
Results First Posted : April 30, 2019
Last Update Posted : April 30, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Narcolepsy With Cataplexy | Drug: Xyrem | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 106 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Actual Study Start Date : | October 1, 2014 |
| Actual Primary Completion Date : | February 2017 |
| Actual Study Completion Date : | January 25, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Xyrem
Active Xyrem at a dose ≤9 g/night
|
Drug: Xyrem |
|
Placebo Comparator: Xyrem Placebo
Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
|
Drug: Xyrem |
- Change in Weekly Number of Cataplexy Attacks [ Time Frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks) ]Double-blind comparison of the change in weekly number of cataplexy attacks from the last 2 weeks of the Stable Dose Period to the 2 weeks of the Double-blind Treatment Period.
- Clinical Global Impression of Change (CGIc) for Cataplexy Severity [ Time Frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks) ]
CGIc for cataplexy severity from the end of the Stable Dose Period to the end of the Double-blind Treatment Period.
The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.
- Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score [ Time Frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks) ]
Change in the ESS (CHAD) score from the end of the Stable Dose Period to the end of the Double-blind Treatment Period.
The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. In the ESS for children and adolescents (CHAD), certain activities were modified. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness.
- CGIc for Narcolepsy Overall [ Time Frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks) ]
CGIc for narcolepsy overall from the end of the Stable Dose Period to the end of the Double-blind Treatment Period.
The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.
- Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period [ Time Frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks) ]
The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning.
The questions and associated point values are separated into the Physical Health (PHS-10 domain) and Psychosocial Health (PSS-10 domain). The sums of the scores in each domain are standardized using the mean and standard deviation from a normal population (2006 sample). The standardized scores are transformed to norm based scoring (NBS) metric. Through NBS, scale scores are standardized to a mean of 50 and SD of 10 in the combined U.S. general population and clinical samples. NBS scores are reported
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 7 Years to 17 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female subjects aged 7-16 years at Visit 2 for subjects on Xyrem at study entry and at Visit 1.1 for Xyrem-naïve subjects (to ensure subjects are <18 years of age at the end of the study)
- Have a primary diagnosis of narcolepsy with cataplexy that meets International Classification of Sleep Disorders (ICSD)-2 or ICSD-3 criteria, whichever was in effect at the time of the diagnosis or, with the permission of the Medical Monitor, completes a Multiple Sleep Latency Test (MSLT) during Screening to confirm the diagnosis of Type 1 narcolepsy by ICSD-3 criteria (i.e., the subject meets all other ICSD-3 criteria for Type 1 narcolepsy)
- Have given documented assent indicating that he/she was aware of the investigational nature of the study and the required procedures and restrictions before participation in any protocol-related activities
- Have parent(s)/guardian(s) who have given informed consent for his/her/their child's participation in the study
- Be willing to spend the required number of nights (2 to 3) in a sleep laboratory for PSG evaluations
- If currently treated with Xyrem, must have been taking unchanged doses (twice nightly dosing no higher than 9 g/night) of Xyrem, and stimulants, if applicable, for the treatment of narcolepsy symptoms for at least 2 months prior to screening
In addition to the above inclusion criteria, subjects participating in the PK evaluation must meet the following inclusion criteria:
7. Be willing to spend 2 additional nights in the clinic for PK evaluation
-
Exclusion Criteria:
- Inability to understand assent or follow study instructions for any reason, in the opinion of the Investigator
- Parent(s) or guardian(s) unable to comply with the requirements of the study for any reason, in the opinion of the Investigator
- Other documented clinically significant condition (including an unstable medical condition, chronic disease other than narcolepsy with cataplexy, or history or presence of another neurological disorder) that might affect the subject's safety and/or interfere with the conduct of the study in the opinion of the Investigator
- Treatment with benzodiazepines, non-benzodiazepine anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates, diclofenac, valproate, phenytoin, ethosuximide within 2 weeks prior to enrollment (discontinuation for the purpose of study enrollment is permitted only if considered safe by the Investigator and approved by the Medical Monitor)
- Treatment with any other medications that have anticataplectic effect (e.g., serotonin-norepinephrine reuptake inhibitors [SNRIs], selective serotonin reuptake inhibitors [SSRIs], or tricyclic antidepressants [TCAs]) within 1 month before Screening
- Unsafe for the subject to receive placebo treatment for 2 weeks, in the opinion of the Investigator
In addition to the above exclusion criteria, subjects participating in the PK evaluation must not demonstrate the following:
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02221869
Show 20 study locations
Documents provided by Jazz Pharmaceuticals:
| Responsible Party: | Jazz Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT02221869 |
| Other Study ID Numbers: |
13-005 |
| First Posted: | August 21, 2014 Key Record Dates |
| Results First Posted: | April 30, 2019 |
| Last Update Posted: | April 30, 2019 |
| Last Verified: | April 2019 |
|
Narcolepsy Cataplexy Disorders of Excessive Somnolence Sleep Disorders, Intrinsic |
Dyssomnias Sleep Wake Disorders Nervous System Diseases Mental Disorders |